Abstract
Treatment-resistant warts are a common and frustrating problem for patients, parents, and providers alike. No wart treatment is uniformly effective. Indeed, well-designed randomized controlled trials are sorely needed to establish the true efficacy of all wart therapies. Treatment should be tailored to each individual patient. Although none of the immunologically-based treatments listed above (see Table, page 377) is FDA-approved for warts, they provide the treating physician with options for patients with warts that are resistant to standard treatments.
MeSH terms
-
Adjuvants, Immunologic / therapeutic use
-
Aminoquinolines / therapeutic use
-
Antigens / therapeutic use
-
Child
-
Child, Preschool
-
Cimetidine / therapeutic use
-
Cyclobutanes / therapeutic use
-
Cyclopropanes / therapeutic use
-
Dinitrochlorobenzene / therapeutic use
-
Histamine H2 Antagonists / therapeutic use
-
Humans
-
Imiquimod
-
Immunotherapy / methods*
-
Injections, Intralesional
-
Irritants / therapeutic use
-
Treatment Outcome
-
Warts / drug therapy*
Substances
-
Adjuvants, Immunologic
-
Aminoquinolines
-
Antigens
-
Cyclobutanes
-
Cyclopropanes
-
Dinitrochlorobenzene
-
Histamine H2 Antagonists
-
Irritants
-
squaric acid dibutyl ester
-
Cimetidine
-
diphenylcyclopropenone
-
Imiquimod